Compugen (CGEN) has released an update.
Compugen Ltd. announced a solid Q2 2024 performance with FDA clearance for COM503 triggering a $30 million milestone payment from Gilead and a strong cash position expected to fund operations until 2027. The company is also preparing to present ovarian cancer study data and anticipates future revenue from AstraZeneca’s development of rilvegostomig, with a potential market of over $5 billion. Compugen’s financial results showed a significant reduction in net loss compared to the previous year and a healthy cash reserve.
For further insights into CGEN stock, check out TipRanks’ Stock Analysis page.
